Regarding oralantidiabetic medication, most of the women with T2DM were taking biguanides (86%),followed by sulphonylureas (40%), dipeptidyl peptidase 4 inhibitors (DPP-4, 34%),sodium-glucose cotransporter (SGLT2, 13.4%), and thiazolidinedione (TZD, 7%).Similarly, biguanides were the major class of oral antidiabetic treatment in menwith T2DM (86%), followed by sulphonylureas (50%) and DPP-4 inhibitors (21%).Approximately 54 and 64% of women and men with T2DM were hypertensive,respectively. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.